Meningococcal vaccines – global drug forecast and market analysis to 2025

The meningococcal vaccine marketplace has traditionally been dominated by Big Pharma, with Sanofi, GlaxoSmithKline (GSK), Pfizer, and Novartis providing the majority of commercially available vaccines over the past decade. Although smaller companies have endeavoured to enter the competitive landscape, those attempts have not resulted in long-lasting success.

During the last few years, the meningococcal vaccine market has experienced additional changes, as Novartis has fully retreated from the market by selling its meningococcal vaccine portfolio to GSK, leaving only three companies in the 8 Major Markets (8MM = US, France, Germany, Italy, Spain, UK, Japan, Brazil) dividing the market share among them.

Of these three pharmaceutical giants, Sanofi has historically been the clear leader with their flagship vaccine Menactra, which not only represented the first tetravalent conjugated meningococcal vaccine but also sustained an excellent market-leading position in the US, even after the launch of competitor vaccines.

However, the lack of diversification in its portfolio and changing serogroup distribution in the different countries has made Sanofi vulnerable to competition. GlobalData expects that GSK will pass Sanofi as the main provider of meningococcal vaccines by the end of this forecast period. This growth in GSK’s market share will be driven by its serogroup B vaccine, Bexsero. Bexsero is currently the only MenB vaccine available in the 5EU (5EU = France, Germany, Italy, Spain, and UK) during the crucial time of broad implementation of routine MenB vaccine administration in the 5EU, making the 5EU the most lucrative region for MenB vaccines during the forecast period.

GlobalData’s report "PharmaPoint: Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2025" will include an interactive excel forecast model based on primary research interviews and surveys with KOLs and high-prescribing physicians. This patient based model provides diagnosis rates, patient segmentation, treatment rates, annual costs of therapy, and indication-specific drug sales for the 10 year forecast period.